以血管紧张素Ⅱ受体拮抗剂为基础的单片复方制剂在高血压患者中的预后的效果
|
摘要
目的分析以血管紧张素Ⅱ受体拮抗剂为基础的单片复方制剂在高血压患者中的预后的效果。方法在该院2017年5月—2018年5月治疗高血压患者中选取80例,并严格按照随机分配原则分为对照组和观察组,各40例。其中对照组口服缬沙坦分散片和苯磺酸氨氯地平片进行治疗,观察组口服厄贝沙坦氢氯噻嗪片进行治疗,观察对比两组患者治疗效果,治疗前后舒张压和收缩压指标及不良反应发生率。结果治疗后,对照组总有效率为90.00%,观察组总有效率为95.00%(χ~2=0.72,P=0.40),对照组不良反应发生率为25.00%,观察组不良反应发生率为22.50%(χ~2=0.07,P>0.05),两组患者治疗前后舒张压和收缩压差异无统计学意义(t=0.06,0.42,0.09,0.16),(P>0.05)。结论予以高血压患者以血管紧张素Ⅱ受体拮抗剂为基础的单片复方制剂均治疗效果显著,可改善其舒张压和收缩压指标,且不会提高不良反应发生率。
Objective To analyze the prognosis of a single-piece combination of angiotensin Ⅱ receptor antagonists in patients with hypertension. Methods Eighty patients with hypertension treated in our hospital from May 2017 to May 2018 were divided into control group and observation group according to the principle of random distribution, 40 cases in each group. The control group was treated with valsartan dispersible tablets and amlodipine besylate tablets. The observation group was treated with irbesartan hydrochlorothiazide tablets. The therapeutic effects, the diastolic blood pressure and systolic blood pressure indexes before and after treatment, and the rate of reaction of the two groups were observed and compared. Results After treatment, the total effective rate of the control group was 90.00%. The total effective rate of the observation group was 95.00%(χ~2=0.72, P=0.40). The incidence of adverse reactions in the control group was 25.00%, and was 22.50% in the observation group(χ~2=0.07, P<0.05). There was no significant difference in diastolic blood pressure and systolic blood pressure between the two groups(t =0.06, 0.42, 0.09, 0.16, P >0.05). Conclusion The monolithic combination preparation based on angiotensin II receptor antagonist in hypertensive patients has significant therapeutic effect, which can improve the diastolic blood pressure and systolic blood pressure indexes, and will not increase the incidence of adverse reactions.
Objective To analyze the prognosis of a single-piece combination of angiotensin Ⅱ receptor antagonists in patients with hypertension. Methods Eighty patients with hypertension treated in our hospital from May 2017 to May 2018 were divided into control group and observation group according to the principle of random distribution, 40 cases in each group. The control group was treated with valsartan dispersible tablets and amlodipine besylate tablets. The observation group was treated with irbesartan hydrochlorothiazide tablets. The therapeutic effects, the diastolic blood pressure and systolic blood pressure indexes before and after treatment, and the rate of reaction of the two groups were observed and compared. Results After treatment, the total effective rate of the control group was 90.00%. The total effective rate of the observation group was 95.00%(χ~2=0.72, P=0.40). The incidence of adverse reactions in the control group was 25.00%, and was 22.50% in the observation group(χ~2=0.07, P<0.05). There was no significant difference in diastolic blood pressure and systolic blood pressure between the two groups(t =0.06, 0.42, 0.09, 0.16, P >0.05). Conclusion The monolithic combination preparation based on angiotensin II receptor antagonist in hypertensive patients has significant therapeutic effect, which can improve the diastolic blood pressure and systolic blood pressure indexes, and will not increase the incidence of adverse reactions.
引文
[1]赵连友,冯颖青.钙拮抗剂/血管紧张素转换酶抑制剂单片复方制剂在高血压治疗中的应用中国专家建议[J].中华高血压杂志,2016,24(1):19-25.
[2]李晓玲,闫素英,王育琴,等.以血管紧张素Ⅱ受体拮抗剂类药物为模板的基本药物遴选方法探讨[J].药物不良反应杂志,2015,32(4):247-252.
[3]陈旸,贺涛,刘明江,等.不同单片复方制剂降压治疗对高血压心脏病预后研究[J].四川医学,2017,38(5):514-517.
[4]王琼.单片复方制剂在高血压治疗中的优势:从降压到降低心血管事件风险[J].中华高血压杂志,2016,24(1):15-18.
[5]罗希.抗高血压单片复方制剂缬沙坦/氨氯地平的药理学研究进展[J].按摩与康复医学,2018,9(12):53-54.
[6]李文,刘明江.以血管紧张素II受体拮抗剂为基础的单片复方制剂对高血压患者治疗预后的影响[J].实用医院临床杂志,2018,15(1):163-165.
[7]周丹凤.厄贝沙坦氢氯噻嗪片与苯磺酸氨氯地平片治疗高血压病的疗效及经济学探讨[J].中国医院用药评价与分析,2016,16(6):753-755.
[8]袁锋,管春静.氯沙坦氢氯噻嗪合剂治疗血管紧张素Ⅱ受体拮抗剂控制无效的高血压患者疗效研究[J].河北医学2014,20(2):210-213.
[9]吴玮芳,陈宝军,王丹丹.固定单片复方制剂治疗高血压的研究进展[J].中国临床药学杂志,2015,16(5):335-338.
[2]李晓玲,闫素英,王育琴,等.以血管紧张素Ⅱ受体拮抗剂类药物为模板的基本药物遴选方法探讨[J].药物不良反应杂志,2015,32(4):247-252.
[3]陈旸,贺涛,刘明江,等.不同单片复方制剂降压治疗对高血压心脏病预后研究[J].四川医学,2017,38(5):514-517.
[4]王琼.单片复方制剂在高血压治疗中的优势:从降压到降低心血管事件风险[J].中华高血压杂志,2016,24(1):15-18.
[5]罗希.抗高血压单片复方制剂缬沙坦/氨氯地平的药理学研究进展[J].按摩与康复医学,2018,9(12):53-54.
[6]李文,刘明江.以血管紧张素II受体拮抗剂为基础的单片复方制剂对高血压患者治疗预后的影响[J].实用医院临床杂志,2018,15(1):163-165.
[7]周丹凤.厄贝沙坦氢氯噻嗪片与苯磺酸氨氯地平片治疗高血压病的疗效及经济学探讨[J].中国医院用药评价与分析,2016,16(6):753-755.
[8]袁锋,管春静.氯沙坦氢氯噻嗪合剂治疗血管紧张素Ⅱ受体拮抗剂控制无效的高血压患者疗效研究[J].河北医学2014,20(2):210-213.
[9]吴玮芳,陈宝军,王丹丹.固定单片复方制剂治疗高血压的研究进展[J].中国临床药学杂志,2015,16(5):335-338.